Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | TAE684 |
Synonyms | |
Therapy Description |
TAE684 inhibits Fes, Alk, and Tnk2 (Ack1) kinase activity, which may result in decreased proliferation of tumor cells (PMID: 17185414, PMID: 25699576, PMID: 22520759, PMID: 32344689). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TAE684 | NVP-TAE684|TAE-684|TAE 684 | ALK Inhibitor 32 TNK2 Inhibitor 6 | TAE684 inhibits Fes, Alk, and Tnk2 (Ack1) kinase activity, which may result in decreased proliferation of tumor cells (PMID: 17185414, PMID: 25699576, PMID: 22520759, PMID: 32344689). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK V1180L | Advanced Solid Tumor | sensitive | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing ALK V1180L in the context of EML4-ALK in culture (PMID: 25228534). | 25228534 |
ALK G1123S ALK F1174L | neuroblastoma | resistant | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, expression of ALK G1123S in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233). | 21948233 |
ALK F1174L ALK L1198P | neuroblastoma | resistant | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, expression of ALK L1198P in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233). | 21948233 |
ALK F856S | hematologic cancer | sensitive | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ALK F856S were sensitive to treatment with TAE684 in culture, demonstrating decreased cell viability (PMID: 26032424). | 26032424 |
ALK G1123D ALK F1174L | neuroblastoma | resistant | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, expression of ALK G1123D in neuroblastoma cells harboring an ALK F1174L mutation resulted in resistance to TAE684 in culture (PMID: 21948233). | 21948233 |
ALK A348D | hematologic cancer | sensitive | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ALK A348D were sensitive to treatment with TAE684 in culture, demonstrating decreased cell viability (PMID: 26032424). | 26032424 |
EML4 - ALK ALK I1171T | Advanced Solid Tumor | sensitive | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, TAE684 inhibited growth of a transformed cell line expressing EML4-ALK ALK I1171T in culture (PMID: 25228534). | 25228534 |
EML4 - ALK ALK L1198P | Advanced Solid Tumor | resistant | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells overexpressing ALK L1198P in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233). | 21948233 |
EML4 - ALK ALK D1203N | Advanced Solid Tumor | resistant | TAE684 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells overexpressing ALK D1203N in the context of EML4-ALK were resistant to TAE684 in culture (PMID: 21948233). | 21948233 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|